Table 1 Demographic characteristics and details at baseline
Characteristics |  | Placebo (n = 27) | BTX-A (25u) (n = 25) | BTX-A (75u) (n = 28) | Total (n = 80) | P value |
|---|---|---|---|---|---|---|
Age, mean (SD), y | Mean (SD) | 58.41 (11.74) | 58.16 (11.54) | 62.64 (13.32) | 59.81 (12.30) | 0.363 |
| Â | Median | 60 | 59 | 63 | 60 | Â |
| Â | Min/max | 31/78 | 41/80 | 40/89 | 31/89 | Â |
Mean months since onset of TN | Mean (SD) | 50.96 (46.26) | 91.96 (72.61) | 72.64 (76.45) | 71.36 (67.68) | 0.181 |
| Â | Median | 36 | 96 | 36 | 48 | Â |
| Â | Min/max | 4/210 | 4/300 | 4/270 | 4/300 | Â |
Sex | Male | 51.85% | 40% | 42.86% | 45% | 0.665 |
Pain intensity,VAS | Mean (SD) | 6.96 (1.97) | 6.24 (2.13) | 7.18 (2.21) | 6.81 (2.12) | 0.197 |
| Â | Median | 7 | 5 | 6.5 | 6 | Â |
| Â | Min/max | 4/10 | 4/10 | 4/10 | 4/10 | Â |